Literature DB >> 19434791

The Birmingham Epidermolysis Bullosa Severity score: development and validation.

C Moss1, A Wong, P Davies.   

Abstract

BACKGROUND: Objective severity scores facilitate clinical care and research. However, the rarity and heterogeneity of epidermolysis bullosa (EB) make scoring difficult.
OBJECTIVES: To develop a severity score covering all subtypes of EB at all ages that is simple, valid, sensitive and reliable.
METHODS: Score items and weightings were generated by expert consensus, and refined for content and face validity. The Birmingham EB Severity (BEBS) score was tested on 97 patients aged 0-64 years.
RESULTS: Eleven items were scored: area of damaged skin, involvement of nails, mouth, eyes, larynx and oesophagus, scarring of hands, skin cancer, chronic wounds, alopecia and nutritional compromise. Area was allocated 50 points, and the 10 other items 5 points each, giving a maximum score of 100. Lowest BEBS scores occurred in Weber-Cockayne EB simplex (median 1.0; range 0.1-3.0; n = 12), highest scores in generalized non-Herlitz junctional EB (28.5; 5.0-62.0; n = 7), Hallopeau-Siemens recessive dystrophic EB (HS-RDEB) (22.9; 4.3-69.0; n = 23) and Herlitz junctional EB (H-JEB) (14.4; 2.5-49.3; n = 9), and intermediate scores in dominant dystrophic EB (5.3; 0.5-15.9; n = 19), Dowling-Meara EB simplex (DM-EBS) (6.3; 2.8-22.5; n = 16) and non-Hallopeau-Siemens recessive dystrophic EB (7.8, 2.8-27.8; n = 11). Intra- and interobserver correlations were high. With age, scores increased for H-JEB (r = 0.9, P = 0.001) and HS-RDEB (r = 0.73, P = 0.001) and decreased for DM-EBS (r = -0.62, P = 0.01), with positive but nonsignificant correlations for the other types.
CONCLUSIONS: The BEBS score appears valid and reproducible, gives appropriate scores for different subtypes, and reflects changes with age.

Entities:  

Mesh:

Year:  2009        PMID: 19434791     DOI: 10.1111/j.1365-2133.2009.09041.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

1.  Birmingham epidermolysis severity score and vitamin D status are associated with low BMD in children with epidermolysis bullosa.

Authors:  G Rodari; S Guez; F Manzoni; K K Chalouhi; E Profka; S Bergamaschi; S Salera; G Tadini; F M Ulivieri; A Spada; C Giavoli; S Esposito
Journal:  Osteoporos Int       Date:  2016-12-23       Impact factor: 4.507

2.  Recommended strategies for epidermolysis bullosa management in romania.

Authors:  Carmen Maria Salavastru; Eli Sprecher; Mihaela Panduru; Johann Bauer; Caius Silviu Solovan; Virgil Patrascu; Horia Silviu Morariu; Anca Tudorache; Torello Lotti; Irene Tagliente; Annalisa Ciasulli; Maria Rosaria Marchili; Giuseppe Sabatino; Erika Burciu; Rodica Cosgarea; Klaus Fritz; George-Sorin Tiplica
Journal:  Maedica (Buchar)       Date:  2013-06

3.  Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa.

Authors:  Marilina Tampoia; Domenico Bonamonte; Angela Filoni; Lucrezia Garofalo; Maria Grazia Morgese; Luigia Brunetti; Chiara Di Giorgio; Giuseppina Annicchiarico
Journal:  Orphanet J Rare Dis       Date:  2013-09-04       Impact factor: 4.123

4.  Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe.

Authors:  Aris Angelis; Panos Kanavos; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Valentin Brodszky; Johann Matthias Graf von der Schulenburg; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-23

5.  Homocysteine metabolism in children and adolescents with epidermolysis bullosa.

Authors:  Rachele De Giuseppe; Greta Venturelli; Sophie Guez; Simona Salera; Claudia De Vita; Dario Consonni; Cinzia Dellanoce; Fabrizia Bamonti; Gabriella Chiarelli; Francesca Manzoni; Rita Maiavacca; Susanna Esposito
Journal:  BMC Pediatr       Date:  2016-10-29       Impact factor: 2.125

6.  The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.

Authors:  S V Jain; A G Harris; J C Su; D Orchard; L J Warren; H McManus; D F Murrell
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-10-03       Impact factor: 6.166

7.  Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy.

Authors:  Sofia von Bischhoffshausen; Dinka Ivulic; Paola Alvarez; Victor C Schuffeneger; Juan Idiaquez; Constanza Fuentes; Pilar Morande; Ignacia Fuentes; Francis Palisson; David L H Bennett; Margarita Calvo
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

Review 8.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

9.  Autoimmunity and Cytokine Imbalance in Inherited Epidermolysis Bullosa.

Authors:  Susanna Esposito; Sophie Guez; Annalisa Orenti; Gianluca Tadini; Giulietta Scuvera; Laura Corti; Alessia Scala; Elia Biganzoli; Emilio Berti; Nicola Principi
Journal:  Int J Mol Sci       Date:  2016-09-24       Impact factor: 5.923

10.  Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa.

Authors:  Giuseppina Annicchiarico; Maria Grazia Morgese; Susanna Esposito; Giuseppe Lopalco; Michele Lattarulo; Marilina Tampoia; Domenico Bonamonte; Luigia Brunetti; Antonio Vitale; Giovanni Lapadula; Luca Cantarini; Florenzo Iannone
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.